One-hour ACPE accredited continuing education program is available at no charge for

pharmacists and pharmacy technicians provided by Pro CE at www.proce.com.

What should I consider when counseling a patient who
is purchasing Levonorgestrel Tablets, 0.75mg?
Tere are approximately three million unplanned pregnancies in the
United States each year and almost half of them end in abortion.
Many are the result of failed contraceptive practices. Patient awareness
of emergency contraception (EC) options may help reduce the
incidence of abortion. Due to the time-sensitive nature of emergency
contraception, it important that you keep Levonorgestrel tablets,
0.75mg in stock and available for purchase. Tey are a generic
product that is bioequivalent and ofers a cost-efective alternative -
to the two tablet Plan B regimen.
Other things your patients should know:
Levonorgestrel tablets, 0.75mg contain two tablets, one which
should be taken as soon as possible after unprotected intercourse, and
another which should be taken 12 hours later.
Some minor side efects such as nausea, vomiting, headache, fatigue,
breast tenderness, dizziness, and abdominal pain may occur, but they
are infrequent and generally mild. If a patient vomits within 2 hours
of taking the medication, it may be necessary for her to repeat the
dose, and she should immediately consult a health care professional.
An anti-emetic may be recommended to lessen the risk of this side
efect.
Changes in the next menstrual cycle may also occur. Most women
will have menses within 7 days of their normal date, although some
will occur earlier or later. Spotting is also common. In very rare cases,
ectopic pregnancy may occur. A physician should be consulted
immediately if abdominal pain occurs 3 to 5 weeks after taking
Levonorgestrel tablets, 0.75mg, or if the next expected menses is
delayed more than reasonably expected, as pregnancy may have
occurred.
It is important to recommend that patients follow routine safe-sex
practices, including the use of male condoms. Levonorgestrel tablets,
0.75mg do not protect against sexually transmitted diseases, are not as
efective as routine methods of birth control when used consistently
and correctly, and will have no efect on an existing pregnancy.
Levonorgestrel tablets, 0.75mg should not be confused with
mifespristone (also known as Mifeprex, RU-486, or the abortion
pill).
For additional resources, and to view citations for the information
contained on this page, please visit:
http://www.Levo4U.com
Please review the attached prescibing information
What are Levonorgestrel Tablets, 0.75mg?
Levonorgestrel the active ingredient in Levonorgestrel tablets,
0.75mg has been used in many daily use oral contraceptives for 35
years. It is designed to prevent unwanted pregnancy in the event that
normal contraceptives fail, are not used, or are not available. Tis
FDA-approved drug has been proven to efectively prevent
approximately 7 of 8 pregnancies that would occur in the absence of
routine contraceptive use, and is efective up to 3 days (72 hours) after
intercourse. Levonorgestrel tablets, 0.75mg are a generic product that
is bioequivalent to the two tablet Plan B product.
Who are Levonorgestrel Tablets, 0.75mg for?
Levonorgestrel tablets, 0.75mg are for any woman who may become
pregnant, but does not want to. Tey are designed for use by any
woman of reproductive age, who do not already have a known or
suspected pregnancy, and do not exhibit hypersensitivity to any of the
ingredients. If normal contraceptive practices fail or are unavailable,
they provide a safe alternative to help prevent pregnancy. Tey are
available as an OTC product for anyone 17 years of age or older, but
may only be dispensed to women under 17 with a prescription. If you
are in a Pharmacy Access state, you may be able to become licensed to
directly prescribe Levonorgestrel tablets, 0.75mg to minors through a
collaborative therapy agreement with a doctor in your area.
When are Levonorgestrel Tablets, 0.75mg effective?
Levonorgestrel tablets, 0.75mg should be used as soon as possible after
unprotected intercourse. Tey can be efective up to 72 hours (3 days)
after unprotected intercourse, but are most efective if taken within 24
hours. Tey are not a primary means of contraception, and use should
be limited to rare cases where normal birth control fails.
Levonorgestrel tablets, 0.75mg may also be used as a supplemental
method of birth control if a patient just isnt sure whether her normal
methods worked. Tey have no efect on an existing pregnancy.
How do Levonorgestrel Tablets, 0.75mg work?
Levonorgestrel tablets, 0.75mg contain the same medication found in
many popular oral contraceptives. By using an elevated dose,
Levonorgestrel tablets, 0.75mg function in the same manner as
routine oral contraceptives to prevent pregnancy by causing a delay in
ovulation, or by interfering with fertilization or the implantation of a
fertilized egg. Te only diference is that Levonorgestrel tablets,
0.75mg can be taken and be efective up to 72 hours after
unprotected intercourse.
Are Levonorgestrel Tablets, 0.75mg abortion?
No. Levonorgestrel tablets, 0.75mg are an
elevated dose of the same drug found in many
common oral contraceptives. It may only
prevent pregnancy. Once pregnancy has
occurred, Levonorgestrel tablets, 0.75mg will
have no efect. If your patient takes
Levonorgestrel tablets, 0.75mg while already
pregnant, or they dont work and she becomes
pregnant, it is not likely to cause any harm to
your patient or her pregnancy.
Do Levonorgestrel Tablets, 0.75mg protect
against sexually transmitted diseases?
No. Levonorgestrel tablets, 0.75mg are a form of
contraception only, and do not protect against
sexually transmitted diseases. Normal safe sex
practices, including the use of condoms and
selective choice in partners, should still be
followed.
Can anyone purchase Levonorgestrel Tablets,
0.75mg?
Anyone 17 years of age or older may purchase
Levonorgestrel tablets, 0.75mg over-the-counter
at a pharmacy with proper identifcation. Tey
are available by prescription only to women
under the age of 17.
Are they safe?
Yes. Levonorgestrel tablets, 0.75mg are a safe,
and FDA-approved, form of emergency
contraception. While some minor side efects
such as nausea, vomiting, headache, fatigue,
breast tenderness, dizziness, and abdominal pain
may occur, they are infrequent and generally
mild. Some changes are usually found during
the next menstrual cycle. In very rare cases,
ectopic pregnancy may occur, and a physician
should be consulted immediately if abdominal
pain occurs 3 to 5 weeks after taking
Levonorgestrel 0.75mg, or if the next expected
menses is delayed more than reasonably
expected, as pregnancy may have occurred. If a
patient vomits within 2 hours of taking the
medication, it may be necessary for her to repeat
the dose.
Accidents happen... And now, Levonorgestrel tablets, 0.75mg ofer a low-cost solution for
women who may be at unexpected risk of pregnancy. Whether your patients regular
methods of birth control failed, she forgot to use her normal methods, or she just feels
unsure - Levonorgestrel tablets, 0.75mg provide a safe and efective second option for added
peace of mind.
Used within the frst 72 hours afer unprotected sex, Levonorgestrel tablets, 0.75mg may
safely and efectively prevent unwanted pregnancy from occurring by providing an elevated
dose of the same medicine found in many daily use oral contraceptives. Let your patient
know about this backup plan...
Levonorgestrel tablets, 0.75mg are available as an over-the-counter (OTC) drug from a pharmacist
for anyone 17 years of age or older, or by prescription only for women under the age of 17.
Important Safety Information Levonorgestrel tablets, 0.75 mg are not effective if youre already pregnant, and they will not terminate an existing pregnancy. Levonorgestrel
tablets, 0.75 mg do not protect against HIV and other sexually transmitted diseases (STDs). Side effects may include nausea, abdominal pain, fatigue, headache, changes in
your period, dizziness, and breast tenderness. If your period is more than a week late, you may be pregnant. If you have severe abdominal pain, you may have an ectopic
pregnancy, and you should get immediate medical help. To report side effects of prescription drugs to the FDA, visit fda.gov/medwatch or call 1-800-FDA-1088. Please see
Prescribing Information to learn more. For more information about Levonorgestrel tablets, 0.75 mg, please call our Levonorgestrel 0.75mg hotline at 1-800-719-9260.
Levonorgestrel tablets, 0.75 mg are available without a prescription for women 17 or older. If you are 16 or younger, a prescription is required. Call your pharmacy to make sure
Levonorgestrel tablets, 0.75 mg are in stock. Plan B

is a registered trademark of Womens Capital Corporation, a subsidiary of DuraMed Pharmaceuticals, Inc.

Levonorgestrel Tablets, 0.75 mg
for women younger than age 17
HIGHLIGHTS OF PRESCRIBING INFORMATION
Tese highlights do not include all the information needed to
use Levonorgestrel tablets, 0.75 mg safely and efectively. See full
prescribing information for Levonorgestrel tablets, 0.75 mg.
Levonorgestrel Tablets, 0.75 mg, for oral use
Initial U.S. Approval: 1982
INDICATIONS AND USAGE
Levonorgestrel tablets, 0.75 mg is a progestin-only emergency
contraceptive, indicated for prevention of pregnancy following
unprotected intercourse or known or suspected contraceptive failure.
Levonorgestrel tablets, 0.75 mg is available only by prescription for
women younger than age 17, and available over the counter for
women 17 years and older. Levonorgestrel tablets, 0.75 mg is not
intended for routine use as a contraceptive. (1)
DOSAGE AND ADMINISTRATION
Te frst tablet is taken orally as soon as possible within 72 hours
after unprotected intercourse. Te second tablet should be taken 12
hours after the frst dose. Efcacy is better if Levonorgestrel tablets,
0.75 mg is taken as soon as possible after unprotected intercourse. (2)
DOSAGE FORMS AND STRENGTHS
A total of two 0.75 mg tablets taken 12 hours apart as a single
course of treatment. (3)
CONTRAINDICATIONS
Known or suspected pregnancy. (4)
WARNINGS AND PRECAUTIONS
Ectopic Pregnancy: Women who become pregnant or
complain of lower abdominal pain after taking
Levonorgestrel tablets, 0.75 mg should be evaluated for
ectopic pregnancy. (5.1)
Levonorgestrel tablets, 0.75 mg is not eective in terminating
an existing pregnancy. (5.2)
Eect on menses: Levonorgestrel tablets, 0.75 mg may alter the
next expected menses. If menses is delayed beyond 1 week,
pregnancy should be considered. (5.3)
STI/HIV: Levonorgestrel tablets, 0.75 mg does not protect
against STI/HIV. (5.4)
ADVERSE REACTIONS
Te most common adverse reactions ( 10%) in the clinical trial
included menstrual changes (26%), nausea (23%), abdominal pain
(18%), fatigue (17%), headache (17%), dizziness (11%), and breast
tenderness (11%). (6.1)
To report SUSPECTED ADVERSE REACTIONS, call 1-800-719-
9260, or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
DRUG INTERACTIONS
Drugs or herbal products that induce certain enzymes, such as CYP3A4,
may decrease the eectiveness of progestin-only pill. (7)
USE IN SPECIFIC POPULATIONS
Nursing Mothers: Small amounts of progestin pass into the
breast milk of nursing women taking progestin-only pills for
long-term contraception, resulting in detectable steroid levels in
infant plasma. (8.3)
Levonorgestrel tablets, 0.75 mg is not intended for use in
premenarcheal (8.4) or postmenopausal females. (8.5)
Clinical trials demonstrated a higher pregnancy rate in the
Chinese population. (8.6)
See 17 for PATIENT COUNSELING INFORMATION
Revised: 8/2009
FULL PRESCRIBING INFORMATION: CONTENTS*
1 INDICATIONS AND USAGE
2 DOSAGE AND ADMINISTRATION
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
5.1 Ectopic Pregnancy
5.2 Existing Pregnancy
5.3 Eect on Menses
5.4 STI/HIV
5.5 Physical Examination and Follow-up
5.6 Fertility Following Discontinuation
6 ADVERSE REACTIONS
6.1 Clinical Trial Experience
6.2 Postmarketing Experience
7 DRUG INTERACTIONS
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
8.3 Nursing Mothers
8.4 Pediatric Use
8.5 Geriatric Use
8.6 Race
8.7 Hepatic Impairment
8.8 Renal Impairment
9 DRUG ABUSE AND DEPENDENCE
10 OVERDOSAGE
11 DESCRIPTION
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
12.3 Pharmacokinetics
13 NONCLINICAL TOXICOLOGY
3.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
14 CLINICAL STUDIES
16 HOW SUPPLIED/STORAGE AND HANDLING
17 PATIENT COUNSELING INFORMATION
17.1 Information for Patients
*Sections or subsections omitted from the full prescribing information are not listed.
For additional information, please visit us on the web at
www.Levo4u.com
www.perrigo.com
FULL PRESCRIBING INFORMATION
1 INDICATIONS AND USAGE
Levonorgestrel tablets, 0.75 mg is a progestin-only emergency
contraceptive indicated for prevention of pregnancy following
unprotected intercourse or a known or suspected contraceptive
failure. To obtain optimal efcacy, the frst tablet should be taken as
soon as possible within 72 hours of intercourse. Te second tablet
should be taken 12 hours later.
Levonorgestrel tablets, 0.75 mg is available only by prescription for
women younger than age 17 years, and available over the counter
for women 17 years and older.
Levonorgestrel tablets, 0.75 mg is not indicated for routine use as a
contraceptive.
2 DOSAGE AND ADMINISTRATION
Take one tablet of Levonorgestrel tablets, 0.75 mg orally as soon as
possible within 72 hours after unprotected intercourse or a known or
suspected contraceptive failure. Efcacy is better if the tablet is taken as
soon as possible after unprotected intercourse. Te second tablet should
be taken 12 hours after the frst dose. Levonorgestrel tablets, 0.75 mg
can be used at any time during the menstrual cycle.
If vomiting occurs within two hours of taking either dose of medication,
consideration should be given to repeating the dose.
3 DOSAGE FORMS AND STRENGTHS
Each Levonorgestrel tablets, 0.75 mg tablet is supplied as a white to
of-white circular, fat beveled, uncoated tablet debossed with
L840 on one side and plain on the other side.
4 CONTRAINDICATIONS
Levonorgestrel tablets, 0.75 mg is contraindicated for use in the
case of known or suspected pregnancy.
5 WARNINGS AND PRECAUTIONS
5.1 Ectopic Pregnancy
Ectopic pregnancies account for approximately 2% of all reported
pregnancies. Up to 10% of pregnancies reported in clinical studies of
routine use of progestin-only contraceptives are ectopic.
A history of ectopic pregnancy is not a contraindication to use of this
emergency contraceptive method. Healthcare providers, however,
should consider the possibility of an ectopic pregnancy in women who
become pregnant or complain of lower abdominal pain after taking
Levonorgestrel tablets, 0.75 mg. A follow-up physical or pelvic
examination is recommended if there is any doubt concerning the
general health or pregnancy status of any woman after taking
Levonorgestrel tablets, 0.75 mg.
5.2 Existing Pregnancy
Levonorgestrel tablets, 0.75 mg is not efective in terminating an
existing pregnancy.
5.3 Efects on Menses
Some women may experience spotting a few days after taking
Levonorgestrel tablets, 0.75 mg. Menstrual bleeding patterns are often
irregular among women using progestin-only oral contraceptives and
women using levonorgestrel for postcoital and emergency
contraception. If there is a delay in the onset of expected menses
beyond 1 week, consider the possibility of pregnancy.
5.4 STI/HIV
Levonorgestrel tablets, 0.75 mg does not protect against HIV infection
(AIDS) or other sexually transmitted infections (STIs).
5.5 Physical Examination and Follow-up
A physical examination is not required prior to prescribing
Levonorgestrel tablets, 0.75 mg. A follow-up physical or pelvic
examination is recommended if there is any doubt concerning the
general health or pregnancy status of any woman after taking
Levonorgestrel tablets, 0.75 mg.
5.6 Fertility Following Discontinuation
A rapid return of fertility is likely following treatment with
Levonorgestrel tablets, 0.75 mg for emergency contraception;
therefore, routine contraception should be continued or initiated as
soon as possible following use of Levonorgestrel tablets, 0.75 mg
to ensure ongoing prevention of pregnancy.
6 ADVERSE REACTIONS
6.1 Clinical Trial Experience
Because clinical trials are conducted under widely varying conditions,
adverse reaction rates observed in the clinical trials of a drug cannot be
directly compared to rates in the clinical trials of another drug and may
not refect the rates observed in clinical practice.
A double-blind, controlled clinical trial in 1,955 evaluable women compared
the efcacy and safety of Levonorgestrel tablets, 0.75 mg (one 0.75 mg tablet of
levonorgestrel taken with 72 hours of unprotected intercourse, and
one tablet taken 12 hours later) to the Yuzpe regimen (two tablets each
containing 0.25 mg levonorgestrel and 0.05 mg ethinyl estradiol, taken
within 72 hours of intercourse, and two tablets taken 12 hours later).
Te most common adverse events ( 10%) in the clinical trial for women
receiving Levonorgestrel tablets, 0.75 mg included menstrual changes
(26%), nausea (23%), abdominal pain (18%), fatigue (17%), headache
(17%), dizziness (11%), and breast tenderness (11%). Table 1 lists those
adverse events that were reported in 5% of Levonorgestrel tablets,
0.75 mg users.
Table 1: Adverse Events in 5% of Women, by % Frequency
6.2 Postmarketing Experience
Te following adverse reactions have been identifed during post-approval
use of Levonorgestrel tablets, 0.75 mg. Because these reactions are
reported voluntarily from a population of uncertain size, it is not always
possible to reliably estimate their frequency or establish a causal
relationship to drug exposure.
Gastrointestinal Disorders
Abdominal Pain, Nausea, Vomiting
General Disorders and Administration Site Conditions
Fatigue
Nervous System Disorders
Dizziness, Headache
Reproductive System and Breast Disorders
Dysmenorrhea, Irregular Menstruation, Oligomenorrhea, Pelvic Pain
7 DRUG INTERACTIONS
Drugs or herbal products that induce enzymes, including CYP3A4, that
metabolize progestins may decrease the plasma concentrations of
progestins, and may decrease the efectiveness of progestin-only pills.
Some drugs or herbal products that may decrease the efectiveness of
progestin-only pills include:
barbiturates
bosentan
carbamazepine
felbamate
griseofulvin
oxcarbazepine
phenytoin
rifampin
St. Johns wort
topiramate
Signifcant changes (increase or decrease) in the plasma levels of the
progestin have been noted in some cases of co-administration with HIV
protease inhibitors or with non-nucleoside transcriptase inhibitors.
Consult the labeling of all concurrently used drugs to obtain further
information about interactions with progestin-only pills or the potential for
enzyme alterations.
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Many studies have found no harmful efects on fetal development
associated with long-term use of contraceptive doses or oral progestins.
Te few studies of infant growth and development that have been
conducted with progestin-only pills have not demonstrated signifcant
adverse efects
For additional information, please visit us on the web at
www.Levo4u.com
www.perrigo.com
8.3 Nursing Mothers
In general, no adverse efects of progestin-only pills have been found on
breastfeeding performance or on the health, growth or development of
the infant. However, isolated post-marketing cases of decreased milk
production have been reported. Small amounts of progestin pass into
the breast milk of nursing mothers taking progestin-only pills for
long-term contraception, resulting in detectable steroid levels in infant
plasma.
8.4 Pediatric Use
Safety and efcacy of progestin-only pills for long-term contraception
have been established in women of reproductive age. Safety and efcacy
are expected to be the same for postpubertal adolescents less than 17
years and for users 17 years and older. Use of Levonorgestrel tablets,
0.75 mg emergency contraception before menarche is not indicated.
8.5 Geriatric
Tis product is not intended for use in postmenopausal women.
8.6 Race
No formal studies have evaluated the efect of race. However, clinical
trials demonstrated a higher pregnancy rate in Chinese women with
both Levonorgestrel tablets, 0.75 mg and the Yuzpe regimen (another
form of emergency contraception). Te reason for this apparent increase
in the pregnancy rate with emergency contraceptives in Chinese women
is unknown.
8.7 Hepatic Impairment
No formal studies were conducted to evaluate the efect of hepatic
disease on the disposition of Levonorgestrel tablets, 0.75 mg.
8.8 Renal Impairment
No formal studies were conducted to evaluate the efect of renal disease
on the disposition of levonorgestrel tablets, 0.75 mg.
9 DRUG ABUSE AND DEPENDENCE
Levonorgestrel tablets, 0.75 mg is not a controlled substance.
There is no information about dependence associated with the use
of Levonorgestrel tablets, 0.75 mg.
10 OVERDOSAGE
There are no data on overdosage of Levonorgestrel tablets,
0.75 mg, although the common adverse event of nausea and
associated vomiting may be anticipated.
11 DESCRIPTION
Each Levonorgestrel tablet contains 0.75 mg of a single active
steroid ingredient, levonorgestrel
[18,19-Dinorpregn-4-en-20-yn-3-one-13-ethyl-17-hydroxy-,
(179)-(-)-], a totally synthetic progestogen.
The inactive ingredients present are colloidal silicon dioxide, corn
starch, lactose monohydrate, magnesium stearate, and providone.
Levonorgestrel has a molecular weight of 312.45, and the
following structural and molecular formulas:
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Emergency contraceptive pills are not efective if a woman is already
pregnant. Levonorgestrel tablets, 0.75 mg is believed to act as an
emergency contraceptive principally by preventing ovulation or
fertilization (by altering tubal transport of sperm and/or ova). In
addition, it may inhibit implantation (by altering the endometrium). It
is not efective once the process of implantation has begun.
12.3 Pharmacokinetics
Absorption
No specifc investigation of the absolute bioavailability of Levonorgestrel
tablets, 0.75 mg in humans has been conducted. However, literature
indicates that levonorgestrel is rapidly and completely absorbed after
oral administration (bioavailability about 100%) and is not subject to
frst pass metabolism.
After a single dose of Levonorgestrel tablets, 0.75 mg administered to 16
women under fasting conditions, the mean maximum serum
concentration of levonorgestrel was 14.1 ng/mL at an average of 1.6
hours. See Table 2.
Table 2: Pharmacokinetic Parameter Values Following Single
Dose Administration of Levonorgestrel Tablets, 0.75 mg to
Healthy Female Volunteers under Fasting Conditions
Cmax = maximum concentration
Tmax = time to maximum concentration
CL = clearance
Vd= volume of distribution
t= elimination half life
AUCinf = area under the drug concentration curve from time
0 to infnity
Efect of Food: Te efect of food on the rate and the extent of
levonorgestrel absorption following single oral administration of
Levonorgestrel tablets, 0.75 mg has not been evaluated.
Distribution
Te apparent volume of distribution of levonorgestrel is reported to be
approximately 1.8 L/kg. It is about 97.5 to 99% protein bound, principally
to sex hormone binding globulin (SHBG) and, to a lesser extent,
serum albumin.
Metabolism
Following absorption, levonorgestrel is conjugated at the 17-OH position
to form sulfate conjugates and, to a lesser extent glucuronide conjugates
in plasma. Signifcant amounts of conjugated and unconjugated
3, 5-tetrahydrolevonorgestrel are also present in plasma, along
with much smaller amounts of 3, 5-tetrahydrolevonorgestrel and
16hydroxylevonorgestrel. Levonorgestrel and its phase 1 metabolites
are excreted primarily as glucuronide conjugates. Metabolic clearance
rates may difer among individuals by several-fold, and this may account
in part for the wide variation observed in levonorgestrel concentrations
among users.
Excretion
About 45% of levonorgestrel and its metabolites are excreted in the urine
and about 32% are excreted in feces, mostly as glucuronide conjugates.
Specifc Populations
Pediatric: Tis product is not intended for use in the premenarcheal
population, and pharmacokinetic data are not available for this population.
Geriatric: Tis product is not intended for use in postmenopausal women,
and pharmacokinetic data are not available for this population.
Race: No formal studies have evaluated the efect of race on
pharmacokinetics of Levonorgestrel tablets, 0.75 mg. However, clinical trials
demonstrated a higher pregnancy rate in Chinese women with both
Levonorgestrel tablets, 0.75 mg and the Yuzpe regimen (another form of
emergency contraception). Te reason for this apparent increase in the
pregnancy rate with emergency contraceptives in Chinese women is
unknown [see USE IN SPECIFIC POPULATIONS (8.6) ].
Hepatic Impairment: No formal studies were conducted to evaluate the
efect of hepatic disease on the disposition of Levonorgestrel tablets, 0.75 mg.
Renal Impairment: No formal studies were conducted to evaluate the efect
of renal disease on the disposition of Levonorgestrel tablets, 0.75 mg.
Drug-Drug Interactions
No formal drug-drug interaction studies were conducted with Levonorgestrel
tablets, 0.75 mg [see DRUG INTERACTIONS (7) ].
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Carcinogenicity: Tere is no evidence of increased risk of cancer with
short-term use of progestins. Tere was no increase in tumorigenicity
following administration of levonorgestrel to rats for 2 years at
approximately 5 g/day, to dogs for 7 years at up to 0.125 mg/kg/day, or to
rhesus monkeys for 10 years at up to 250 g/kg/day. In another 7 year dog
study, administration of levonorgestrel at 0.5 mg/kg/day did increase the
number of mammary adenomas in treated dogs compared to controls.
Tere were no malignancies.
Genotoxicity: Levonorgestrel was not found to be mutagenic or genotoxic in
the Ames Assay, in vitro mammalian culture assays utilizing mouse
lymphoma cells and Chinese hamster ovary cells, and in an in vivo
micronucleus assay in mice.
Fertility: Tere are no irreversible efects on fertility following cessation of
exposures to levonorgestrel or progestins in general.
For additional information, please visit us on the web at
www.Levo4u.com
www.perrigo.com
14 CLINICAL STUDIES
A double-blind, randomized, multinational controlled clinical trial
in 1,955 evaluable women (mean age 27) compared the efcacy and
safety of Levonorgestrel tablets, 0.75 mg (one 0.75 mg tablet of
levonorgestrel taken within 72 hours of unprotected intercourse, and
one tablet taken 12 hours later) to the Yuzpe regimen (two tablets each
containing 0.25 mg levonorgestrel and 0.05 mg ethinyl estradiol, taken
within 72 hours of intercourse, and two additional tablets taken 12
hours later). After a single act of intercourse occurring anytime during
the menstrual cycle, the expected pregnancy rate of 8% (with no
contraceptive use) was reduced to approximately 1% with
Levonorgestrel tablets, 0.75 mg.
Emergency contraceptives are not as efective as routine hormonal
contraception since their failure rate, while low based on a single use,
would accumulate over time with repeated use [see INDICATIONS
AND USAGE (1) ].
At the time of expected menses, approximately 74% of women using
Levonorgestrel tablets, 0.75 mg had vaginal bleeding similar to their
normal menses, 14% bled more than usual, and 12% bled less than
usual. Te majority of women (87%) had their next menstrual period at
the expected time or within + 7 days, while 13% had a delay of more
than 7 days beyond the anticipated onset of menses.
16 HOW SUPPLIED / STORAGE AND HANDLING
Levonorgestrel tablets, 0.75 mg are available for a single course of
treatment in PVC/aluminum foil blister packages of two tablets
each. Te tablet is white to of-white, circular, fat beveled,
uncoated tablet debossed with L840 on one side and plain on the
other side.
Available as: Unit-of-use NDC 45802-BF-54
Store Levonorgestrel tablets, 0.75 mg at controlled room
temperature, 20 to 25C (68 to 77F); excursions permitted
between 15 to 30C (59 to 86F) [See USP].
17 PATIENT COUNSELING INFORMATION
17.1 Information for Patients
Take Levonorgestrel tablets, 0.75 mg as soon as possible and not
more than 72 hours after unprotected intercourse or a known or
suspected contraceptive failure.
If you vomit within two hours of taking either tablet, immediately
contact your healthcare provider to discuss whether to take
another tablet.
Seek medical attention if you experience severe lower abdominal
pain 3 to 5 weeks after taking Levonorgestrel tablets, 0.75 mg, in
order to be evaluated for an ectopic pregnancy.
After taking Levonorgestrel tablets, 0.75 mg, consider the possibility
of pregnancy if your period is delayed more than one week beyond
the date you expected your period.
Do not use Levonorgestrel tablets, 0.75 mg as routine
contraception.
Levonorgestrel tablets, 0.75 mg is not efective in terminating an
existing pregnancy.
Levonorgestrel tablets, 0.75 mg does not protect against
HIV-infection (AIDS) and other sexually transmitted
diseases/infections.
For women younger than age 17 years, Levonorgestrel tablets,
0.75 mg is available only by prescription.
Product Made in India
MANUFACTURED BY
CIPLA LTD.,
MUMBAI, INDIA
DISTRIBUTED BY
ALLEGAN, MI 49010
Phone: 1-800-719-9260 Website: www.Levo4U.com
Rev 08/09
For additional information, please visit us on the web at
www.Levo4u.com
www.perrigo.com